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Abstract
Introduction: It is unknown to what extent use of palliative care and focus on proactive planning of end-of-life
(EOL) care among cancer patients is also reflected by less use of intensive care. We aimed to examine the use of
intensive care in the EOL in patients dying as a result of non-cancer diseases compared with patients dying due
to cancer.
Methods: We conducted a nationwide follow-up study among 240,757 adults dying as a result of either
non-cancer chronic disease or cancer in Denmark between 2005 and 2011. Using the Danish Intensive Care
Database, we identified all admissions and treatments in intensive care units (ICU) during the patients’ last
6 months before death. We used prevalence ratios (aPRs) adjusted for age, sex, comorbidity, marital status and
residential region to compare the 6-month prevalence of ICU admissions as well as treatment with invasive
mechanical ventilation (MV), non-invasive ventilation (NIV), renal replacement therapy (RRT) and inotropes and/or
vasopressors. In addition, length of ICU stay and death during ICU admission were compared among non-cancer
and cancer patients dying between 2009 and 2011.
Results: Overall 12.3 % of non-cancer patients were admitted to an ICU within their last 6 months of life, compared
with 8.7 % of cancer patients. The overall aPR for ICU admission was 2.11 [95 % confidence interval (CI) 1.98–2.24]
for non-cancer patients compared with cancer patients and varied widely within the non-cancer patients (patients
with dementia, aPR 0.19, 95 % CI 0.17–0.21; patients with chronic obstructive lung disease, aPR 3.19, 95 % CI 2.97–3.41).
The overall aPRs for treatment among non-cancer patients compared with cancer patients were 1.40 (95 % CI
1.35–1.46) for MV, 1.62 (95 % CI 1.50–1.76) for NIV, 1.19 (95 % CI 1.07–1.31) for RRT and 1.05 (95 % CI 0.87–1.28) for
inotropes and/or vasopressors. No difference in admission length was observed. Non-cancer patients had an increased
risk of dying in an ICU (aPR 1.23, 95 % CI 0.99–1.54) compared with cancer patients.
Conclusions: Overall, patients dying as a result of non-cancer diseases were twice as likely to be admitted to ICUs at
the EOL as patients dying due to cancer. Further studies are warranted to explore whether this difference in use of
intensive care reflects an unmet need of palliative care, poor communication about the EOL or lack of prognostic tools
for terminally ill non-cancer patients.
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Introduction
Chronic disease remains the dominant cause of death
globally, with cancer being the leading cause [1], followed
by heart, cerebrovascular and lung diseases [2]. Patients
with chronic disease require increased care, which may in-
clude intensive care, at the end of life (EOL) [3], defined
as the last 6 months before death. Ageing populations
translate to a higher prevalence of chronic diseases [4],
and therefore increased spending on EOL care in the
coming years is expected. More than one-fourth of all
health care costs in the United States are already being in-
curred during the last year of patients’ lives [5]. The ma-
jority (>80 %) of these expenses are for intensive care [6].
Use of palliative treatment is increasing, particularly
for cancer patients [7]. However, studies have shown
that patients with heart failure experience a burden of
symptoms similar to that of patients with advanced can-
cer [8]. In addition, patients with chronic obstructive
pulmonary disease (COPD) were found to receive less
palliative care at the EOL than patients with lung cancer,
despite having comparable symptoms [9], and were more
likely than cancer patients to die in a hospital setting in-
stead of at home [10].
Intensive care may constitute a substantial emotional
and physiological burden for both patients and their
relatives [11]. Deciding who should be admitted to an
intensive care unit (ICU) remains a difficult task; how-
ever, a widely accepted consensus is that a considerable
prospect of recovery must exist [12]. Meanwhile, ensur-
ing relevant, high-quality care that meets the expecta-
tions of patients and their relatives at all stages of illness
in a health care system with limited resources is a major
challenge [5]. Timely recognition of a non-curative disease
stage and open discussions about prognosis and prefer-
ences could presumably ease this task [13, 14]. Existing
research on the use of intensive care during the EOL has
been focused on few diagnoses [9] or variation over time
[10] or has not actually compared the differences between
patients or diagnostic groups [3, 6, 15], leaving a require-
ment for more data on variation in use of intensive care to
provide a better understanding of disease patterns and
thereby support clinicians in the rational use of intensive
care for patients with cancer and other chronic diseases.
The differences in care patterns between non-cancer
and cancer patients are of particular interest because an
increased level of care at the EOL does not seem to be
associated with better survival, higher functional status
or improved quality of life [16, 17], nor has it been shown
to be aligned with patients’ preferences for treatment and
place of death, leaving many patients without the care they
wish for in their final months of life [18, 19].
The nationwide clinical databases and population-
based medical registries in Denmark provide a unique
opportunity to investigate the use of intensive care at
the EOL in a setting with equal and universal access to
health care. The aim of this study was to examine the
use of intensive care and death in the ICU at the EOL
and compare patients who died as a result of non-cancer
chronic diseases with those who died due to cancer.
Methods
Study design and setting
We conducted this nationwide follow-up study in
Denmark, a country with a population of approximately
5.6 million. The health care system of Denmark is fi-
nanced through federal taxes and provides equal, universal
access to hospital care, including intensive care, for all citi-
zens. More than 98 % of Danish citizens are registered
with a general practitioner (GP). GPs act as gatekeepers
for access to specialists and hospital treatment. Interdis-
ciplinary palliative specialist teams are available for referral
from GPs and hospital specialists [20]. Denmark encom-
passes 49 ICUs (2011). Unambiguous individual-level link-
age between population-based registries was performed
using the unique civil registration number assigned to
each Danish citizen at birth and to residents upon immi-
gration [21].
Study population
The Danish Registry of Causes of Death was used to
identify the underlying cause of death for all decedents
from the age of 18 years who died between 1 January
2005 and 31 December 2011. The Danish Registry of
Causes of Death contains data on all decedents since
1970, and data entry is mandatory by law. Data include,
among others, civil registration number; date of death;
manner of death; and cause of death, both immediate
and underlying, coded according to the Danish version
of the International Classification of Diseases, Tenth
Revision [22]. We grouped the underlying causes of death
into two groups: cancer or non-cancer (diabetes, de-
mentia, ischaemic heart disease, congestive heart failure,
cerebrovascular disease, COPD and chronic liver disease)
(Additional file 1). These eight causes of death were the
most common in Denmark in the 2005–2011 period [23].
The remaining causes of death were grouped as ‘other’
and comprised 144,010 individuals (37.4 %) who were
excluded from the analyses. Likewise, 48 patients (<0.1 %)
with missing information on residential region were
excluded.
Intensive care
Data on ICU admission within the last 6 months before
death were identified through the Danish Intensive Care
Database (DID). The DID is a clinical database estab-
lished for nationwide quality monitoring and holds data
from 2005 and onwards for patients admitted to any
ICU in Denmark. Data entry is mandatory by law. The
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positive predictive value of data on ICU admissions in
the DID has been found to be between 87.2 % and
98.7 % [24, 25]. Data include, among others, information
on admission date; discharge status, including death in
an ICU; invasive mechanical ventilation (MV); non-
invasive ventilation (NIV); inotrope and/or vasopressor
therapy; and renal replacement therapy (RRT) [26].
Comorbidities
We obtained data on comorbid conditions using diagno-
ses from hospital admissions and outpatient clinical
visits recorded in the Danish National Registry of Patients
in up to the 10 years preceding death. We assessed co-
morbidity level by means of the Charlson comorbidity
index (CCI) [27]. This scoring system assigns between 1
and 6 points to each of the 19 conditions. The standard
CCI was calculated from the sum of weights for the 19
diseases [27]. We further modified the CCI by deducting
points for the underlying cause of death if it was also
present as comorbidity. We then calculated modified
scores summing the weights for the other comorbid con-
dition (Additional file 2). This was done to avoid including
diseases in the analyses as both comorbid conditions and
causes of death. Patients with a modified CCI score ≥1
were categorised as ‘any comorbidity’, and patients with a
modified CCI of 0 were categorised as ‘no comorbidity’.
Statistical analyses
The period prevalence of admission to ICU within
6 months before death for patients dying as a result of
non-cancer chronic diseases and for patients dying due
to cancer was calculated and compared by adjusted
prevalence ratios (aPRs), which were estimated using
multivariable binomial regression adjusted for age, sex,
comorbidity and marital status. In all adjusted analyses,
we accounted for potential clustering by residential
region. We repeated the analyses stratified by age groups
and sex. Next, we calculated the prevalence proportions
of patients treated with invasive MV, NIV, RRT and ino-
tropes and/or vasopressors among patients admitted to
an ICU within the last 6 months before death. Analyses
were stratified according to age and sex. Aggressiveness
of treatment was defined as either ‘full organ supportive
treatment’ (i.e., the patient received respiratory support
by MV and/or NIV, vasopressor and/or inotropes and
RRT during ICU admissions in the last 6 months of life)
or as ‘partial organ supportive treatment’ (i.e., the patient
received treatment in two or less of the three treatment
modalities assessed) (Additional file 3). We calculated
the median length of ICU stay along with the interquar-
tile range (IQR). Due to availability of data in the DID,
we restricted this analysis to the years 2009–2011. Fi-
nally, we calculated the proportion of deaths occurring
in an ICU. This analysis was also restricted to the years
2009–2011 due to the availability of these data in the
DID. The proportions of deaths in ICUs were compared
for the non-cancer and cancer patients using multi-
variable binomial regression adjusted for age, sex, any
comorbidity and marital status.
All statistical analyses were performed using Stata soft-
ware (Stata/IC version 13.1; StataCorp, College Station,
TX, USA). In accordance with National Committee on
Health Research Ethics guidelines, non-interventional
studies do not require approval from ethics committees
in Denmark. The study was approved by the Danish




We included a total of 240,757 adult decedents during the
7-year study period (Fig. 1). Among these individuals,
Fig. 1 Flowchart depicting inclusion criteria of study population and grouping of cancer and non-cancer patients [number (%)]. ICU intensive care unit
Lyngaa et al. Critical Care  (2015) 19:413 Page 3 of 9
134,298 (55.8 %) died as a result of the included non-
cancer diseases and 106,459 (44.2 %) died due to cancer.
The median ages were 82 years for non-cancer patients
and 74 years for cancer patients. Women comprised
52.6 % of the non-cancer group and 48.7 % of the cancer
group (Table 1).
ICU admission
Within the last 6 months before death, 25,796 (10.7 %)
of all patients were admitted to an ICU (Table 1), ac-
counting for 12.3 % of the non-cancer patients and
8.7 % of the cancer patients. The overall aPRs for admis-
sion to an ICU during the last 6 months before death
were 2.11 [95 % confidence interval (CI) 1.98–2.24)
among patients dying of non-cancer disease compared
with cancer. Compared with cancer patients, those dying
of COPD were more likely to be admitted to an ICU
during EOL (aPR 3.19 (95 % CI: 2.97–3.41)), while pa-
tients dying of dementia were less likely to be admitted
to an ICU (aPR 0.19 (95 % CI: 0.17–0.21)) (Table 2).
Figure 2 shows the prevalence of ICU admission by
age group and sex. For both sexes, we found the highest
aPRs for the 50–59-year-old age group (aPR women
3.77, 95 % CI 3.36–4.22; aPR men 2.14, 95 % CI 2.02–
2.27) when we compared non-cancer patients with can-
cer patients. The difference between non-cancer and
cancer patients progressively declined with age for both
sexes, with the age 90+ years group having the lowest
aPR estimates (aPR women 0.60, 95 % CI 0.50–0.73; aPR
men 0.85, 95 % CI 0.65–1.11) (Fig. 2).
ICU treatment
Table 3 displays data on the use of ICU-specific treat-
ment modalities. Overall, these modalities were used
more often in non-cancer patients than for cancer pa-
tients. Of the non-cancer patients, 55.6 % versus 42.2 %
of the cancer patients received MV, corresponding to an
aPR 1.40 (95 % CI 1.35–1.46). NIV treatment was given
to 27.3 % of the non-cancer patients and 16.4 % of the
cancer patients (aPR 1.62, 95 % CI 1.50–1.76), ranging
from aPRs of 0.51 (95 % CI 0.45–0.58) for patients dying
as a result of dementia to 3.40 (95 % CI 3.00–3.85) for
patients dying due to COPD. Treatment with inotropes
or vasopressors was used in 44.3 % of the non-cancer
patients and 38.9 % of the cancer patients, resulting in
an overall aPR of 1.19 (95 % CI 1.07–1.31), whereas no
difference in use of RRT was observed (aPR 1.05, 95 %
CI 0.87–1.28). No patients with dementia were treated
with RRT, whereas the highest aPR was found among
patients dying as a result of diabetes (aPR 2.27, 95 % CI
1.91–2.69) (Table 3).
When we examined the combination of treatments
(Additional file 3), we found that the proportions
receiving full organ supportive treatment were 6.9 %
among the non-cancer patients and 7.5 % among the
cancer patients. No difference between non-cancer pa-
tients and cancer patients was observed after controlling
for the aforementioned potential confounding (overall
aPR 1.02, 95 % CI 0.82–1.27). However, no patients who
were dying as a result of dementia received full organ sup-
portive treatment, and the highest aPR was found among
patients dying due to diabetes (aPR 1.98, 95 % CI 1.60–
2.44) (Table 3).
Length of ICU stay
The overall median length of stay per ICU admission
within the last 6 months before death was 29.5 h for the
non-cancer patients (IQR 10.1–87.6). For cancer pa-
tients, the corresponding number was 29.7 h (IQR 13.2–
94.5) (Table 4).
ICU death
The overall proportion of patients dying during ICU ad-
mission was 35.5 % among non-cancer patients and
29.2 % for cancer patients. We found an overall increased
risk of dying during ICU admission for non-cancer in
comparison with cancer patients (aPR 1.23, 95 % CI 0.99–
1.54) (data not shown).
Discussion
In this Danish nationwide study, we found considerably
higher use of ICU admission at the EOL among patients
dying as a result of non-cancer chronic diseases than
among patients dying due to cancer. In comparison with
patients dying due to cancer, patients with dementia as
the underlying cause of death were unlikely to be admit-
ted to the ICUs and received less treatment, whereas the
opposite was the case for patients dying as a result of
COPD or diabetes. Whereas there was no overall differ-
ence in the prevalence of full organ supportive treatment
between non-cancer and cancer patients, patients dying
as a result of diabetes or heart disease received full organ
supportive treatment almost two times more often than
cancer patients did.
The findings of our study are supported by those of a
smaller U.S. study [9] in which researchers compared
the health care resource use of 1490 patients with COPD
at Veteran Affairs medical centres with 459 patients with
lung cancer. Those authors found that patients with
COPD were twice as likely to be admitted to an ICU in
the last 6 months before death as those with lung can-
cer. In our study, we found that patients dying as a
result of COPD were admitted to an ICU three times
more often than all patients dying due to cancer.
Whereas the sample population in the U.S. study was
predominantly elderly white men, our study included
both men and women. The difference in case mix
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Table 1 Characteristics of decedents between 2005 and 2011, stratified by underlying cause of death as either cancer or chronic
non-cancer disease
Chronic non-cancer disease,
n (% of all non-cancer patients)
Cancer, n (% of all
cancer patients)
Total study population,
n (% of all decedents)
Overall number (%) 134,298 (100.0 %) 106,459 (100.0 %) 240,757 (100.0 %)
Median age [IQR], yr 82 [74–89] 74 [65–82] 79 [69–86]
Age group, stratified by sex
18–49 yr, female 922 (0.7 %) 2483 (2.3 %) 3405 (1.4 %)
18–49 yr, male 2121 (1.6 %) 1973 (1.9 %) 4094 (1.7 %)
50–59 yr, female 2232 (1.7 %) 5742 (5.4 %) 7974 (3.3 %)
50–59 yr, male 4650 (3.5 %) 5809 (5.5 %) 10,459 (4.3 %)
60–69 yr, female 5309 (4.0 %) 11,772 (11.1 %) 17,081 (7.1 %)
60–69 yr, male 9745 (7.3 %) 14,043 (13.2 %) 23,788 (9.9 %)
70–79 yr, female 13,789 (10.3 %) 14,939 (14.0 %) 28,728 (11.9 %)
70–79 yr, male 16,854 (12.5 %) 17,650 (16.6 %) 34,504 (14.3 %)
80–89 yr, female 29,629 (22.1 %) 13,396 (12.6 %) 43,025 (17.9 %)
80–89 yr, male 22,991 (17.1 %) 13,042 (12.3 %) 36,033 (15.0 %)
90+ yr, female 18,818 (14.0 %) 3469 (3.3 %) 22,287 (9.3 %)
90+ yr, male 7238 (5.4 %) 2141 (2.0 %) 9379 (3.9 %)
Sex
Female 70,699 (52.6 %) 51,801 (48.7 %) 122,500 (50.9 %)
Male 63,599 (47.4 %) 54,658 (51.3 %) 118,257 (49.1 %)
Marital status
Married 42,635 (31.7 %) 53,771 (50.5 %) 96,406 (40.0 %)
Unmarried 17,158 (12.8 %) 14,045 (13.2 %) 31,203 (13.0 %)
Divorced 12,512 (9.3 %) 8494 (8.0 %) 21,006 (8.7 %)
Widowed 61,993 (46.2 %) 30,149 (28.3 %) 92,142 (38.3 %)
Geographical region of residence
North Denmark Region 15,715 (11.7 %) 11,931 (11.2 %) 27,646 (11.5 %)
Central Denmark Region 27,689 (20.6 %) 22,428 (21.1 %) 50,117 (20.8 %)
Region of Southern Denmark 31,080 (23.1 %) 23,669 (22.7 %) 54,749 (22.7 %)
Capital Region of Denmark 38,138 (28.4 %) 30,680 (28.6 %) 68,818 (28.6 %)
Region Zealand 21,676 (16.1 %) 17,751 (16.7 %) 39,427 (13.4 %)
Cause of death
Cancer – 106,456 (100.0 %) 106,456 (44.2 %)
Non-cancer chronic diseases 134,298 (100.0 %) – 134,298 (55.8 %)
Diabetes 9150 (6.8 %) – 9150 (3.8 %)
Dementia 18,298 (13.6 %) – 18,298 (7.6 %)
Ischaemic heart disease 39,466 (29.4 %) – 39,466 (16.4 %)
Heart failure 10,779 (8.0 %) – 10,779 (4.5 %)
Cerebrovascular disease 28,522 (21.2 %) – 28,522 (11.9 %)
COPD 22,120 (16.5 %) – 22,120 (9.2 %)
Chronic liver failure 5963 (4.4 %) – 5963 (2.3 %)
ICU admissiona
No 117,796 (87.7 %) 97,165 (91.3 %) 214,961 (89.3 %)
Yes 16,502 (12.3 %) 9294 (8.7 %) 25,796 (10.7 %)
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between the U.S. study and our study could likely ex-
plain the higher admission rate in our study, as our find-
ings suggest that the rates of admission to the ICU were
lower among men than among women.
To our knowledge, no previous studies have directly
evaluated the risk of dying in an ICU for non-cancer pa-
tients compared with cancer patients. One U.S. study
measured terminal admissions associated with intensive
care among non-federal hospitals in six states as a meas-
ure of death during ICU admission [6]. The results of
that study were that 22.4 % of patients died in hospital
after ICU admission. Another U.S. study assessed preva-
lence of death among patients using intensive care ser-
vices during terminal hospitalisation in England and the
United States [15]. The investigators in that study found
hospital mortality among the patients who were admitted
to ICUs in England to be 19.6 % and 7.4 % in the United
States. In neither of these studies were distinctions made
between non-cancer and cancer causes of death. In our
study, we were able to assess the prevalence of death dur-
ing ICU admissions among all patients dying as a result of
non-cancer diseases and compare it with the prevalence of
ICU deaths among all patients dying due to cancer. When
we adjusted for confounders, we found dying in an ICU to
be more likely to be associated with dying as a result of
non-cancer diseases than dying due to cancer. Bearing in
mind that only about half of cancer patients have their
wishes fulfilled regarding place of death [19], this adds to
the need for a better understanding of the large variation
in care patterns between non-cancer patients and cancer
patients at the EOL.
We found substantial variation in health care at the
EOL, which is consistent with the previously mentioned
studies, indicating that triage may be based more on
diagnosis and less likely to be driven by symptoms and
prognosis, thus raising a question whether treatment is
aligned with patients’ preferences.
A number of limitations should be taken into consid-
eration when interpreting our results. First, we examined
intensive care during the EOL using a decedent-only
sample. This approach has been criticized, as it artifi-
cially removes the uncertainty of prognostication in pa-
tients near the EOL [28]. However, with the data
available for this study, it was not possible to determine
when patients with non-cancer chronic conditions entered
the terminal phase, which made a traditional follow-up
study among all patients with these conditions difficult.
We therefore included all adult decedents who died as a
result of the eight specified chronic diseases during the
study period. Cause of death was determined as the
underlying cause of death derived from the Danish Regis-
try of Causes of Death. The Danish Registry of Causes of
Death is practically complete [22]. We based our analyses
on the underlying cause of death due to well-defined
chronic diseases. However, determining the causes of
death—both underlying and immediate—can be difficult.
Validation of the Danish Registry of Causes of Death has
been performed only for some diseases [29], leaving some
uncertainty about classification of the causes of death.
This could introduce misclassification that is likely to be
independent of ICU admission (i.e., non-differential),
which would bias the results towards the null association.
In this study, we aimed to control for confounding by
adjusting for a range of known potential confounders;
however, unmeasured confounding cannot be ruled out.
Of the variables we included in our study, those affecting
the estimates most were age, sex and marital status.
In the ELDICUS project [12], a wide array of intensive
care experts generally agreed on a range of principles
expressed in a large consensus statement regarding the
triage of ICU patients. Among these was that there must
Table 1 Characteristics of decedents between 2005 and 2011, stratified by underlying cause of death as either cancer or chronic
non-cancer disease (Continued)
Comorbidityb
No 48,299 (36.0 %) 32,876 (30.9 %) 81,175 (33.7 %)
Yes 85,999 (64.0 %) 73,583 (69.1 %) 159,582 (66.3 %)
COPD chronic obstructive pulmonary disease, ICU intensive care unit, IQR interquartile range
aAny admission to an ICU within the last 6 months before death
bCalculated as Charlson comorbidity index diseases, excluding underlying cause of death
Table 2 ICU admission during the last 6 months before death,
by cause of death
ICU admission
Causes of death Admitted to ICU (%) aPR 95 % CI
Cancer 8.7 % 1.00 Reference
Chronic non-cancer diseases 12.3 % 2.11 1.98–2.24
Diabetes 11.4 % 1.58 1.34–1.86
Dementia 0.7 % 0.19 0.17–0.21
Ischaemic heart disease 10.2 % 1.69 1.52–1.88
Heart failure 9.8 % 1.95 1.86–2.03
Cerebrovascular disease 13.2 % 2.39 2.17–2.63
Chronic obstructive
pulmonary disease
31.9 % 3.19 2.98–3.41
Chronic liver failure 27.4 % 2.42 1.94–3.03
aPR adjusted prevalence ratio (adjusted for age, sex, marital status, any
comorbidity and geographic region), CI confidence interval, ICU intensive
care unit
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be a considerable prospect for the patient to recover. If
symptoms experienced by non-cancer patients are simi-
lar to or worse than symptoms experienced by cancer
patients [8, 9, 30], then treatment should vary only by a
little. However, difficulties in predicting trajectories for
non-cancer chronic diseases are offered as an explanation
of the existence of differences in treatment [13, 14, 31].
This difficulty is also reflected in the reduced tendency to
recognize these patients as having a terminal prognosis
[32]. The descriptive nature of the present study does not
allow us to determine whether the observed dif-
ferences in use of intensive care during the EOL are
appropriate; we can only speculate about this. None-
theless, the difference in ICU use between non-cancer
and cancer patients found in this study warrants
consideration of whether the current allocation of
Fig. 2 Forest plot of the adjusted prevalence ratios for admission to an intensive care unit (ICU) within the last 6 months before death among
patients dying as a result of non-cancer chronic diseases compared with patients dying due to cancer. CI confidence interval
Table 3 Treatment in the ICU during the last 6 months before death, by cause of death
Mechanical ventilation NIV Inotropes/vasopressors Dialysis Full organ supportive treatment
Causes of death % aPR 95 % CI % aPR 95 % CI % aPR 95 % CI % aPR 95 % CI % aPR 95 % CI
Cancer 42.2 1.00 Reference 16.4 1.00 Reference 38.9 1.00 Reference 9.7 1.00 Reference 7.5 1.00 Reference
Chronic non-cancer
diseases
55.6 1.40 1.35–1.46 27.3 1.62 1.50–1.76 44.3 1.19 1.07–1.31 9.4 1.05 0.87–1.28 6.9 1.02 0.82–1.27
Diabetes 49.7 1.27 1.16–1.39 17.3 1.03 0.94–1.14 48.2 1.31 1.18–1.46 22.2 2.27 1.91–2.69 14.3 1.98 1.60–2.44
Dementia 25.6 0.80 0.68–0.94 11.3 0.64 0.46–0.88 16.5 1.31 1.18–1.46 0 – – 0 – –
IHD 59.3 1.57 1.53–1.61 16.4 0.96 0.90–1.03 62.5 0.54 0.39–0.73 14.0 1.60 1.20–2.14 11.0 1.70 1.31–2.20
Heart failure 49.8 1.36 1.22–1.51 27.8 1.64 1.53–1.75 52.2 1.72 1.60–1.86 14.5 1.74 1.33–2.28 10.2 1.66 1.16–2.39
Stroke 69.6 1.66 1.60–1.71 8.2 0.51 0.45–0.58 33.3 1.49 1.32–1.68 3.6 0.40 0.32–0.50 2.64 0.37 0.29–0.48
COPD 43.3 1.11 1.01–1.22 58.5 3.40 3.00–3.85 33.3 0.86 0.72–1.03 5.3 0.62 0.46–0.84 3.8 0.59 0.38–0.91
CLF 61.1 1.30 1.14–1.47 13.4 0.90 0.81–1.01 52.2 0.90 0.79–1.03 12.6 1.19 0.90–1.56 9.4 1.12 0.83–1.52
aPR adjusted prevalence ratio (adjusted for age, sex, marital status, any comorbidity and geographic region), CI confidence interval, COPD Chronic obstructive
pulmonary disease, CLF Chronic liver failure, IHD ischaemic heart disease
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ICU beds is optimal and how to better accommodate
the demands of care for non-cancer patients at the
EOL.
Conclusions
In our study, we found that patients dying as a result of
non-cancer diseases were twice as likely as patients
dying due to cancer to be admitted to an ICU at the
EOL. We also found that non-cancer patients may be
more likely than cancer patients to die during an ICU
admission. These findings add to the body of literature
describing the substantial unwarranted variation in
health care at the EOL. They also emphasize the need
for further investigation into reasons behind this vari-
ation to enable provision of the optimal care for patients
at the EOL, regardless of diagnosis.
Key messages
 Patients dying as a result of non-cancer chronic
diseases are two times likelier than patients dying
due to cancer to be admitted to an ICU within
6 months before they die.
 Non-cancer patients may be likelier than cancer
patients to die during an ICU admission.
 Substantial variation was found among the causes of
death regarding admission to an ICU and treatment
during ICU admission at the EOL.
Additional files
Additional file 1: Cumulative prevalence of causes of death,
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18 years and older. ICD-10 diagnoses were used to define chronic
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ischemic heart disease, cerebrovascular disease, and chronic obstructive
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